Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enalapril and folic acid for prevention of contrast-induced nephropathy after PCI
ChiCTR-IPR-17011268Phase 4Not yet recruiting
- Sponsor
- Zhongda Hospital, Southeast University
- Start
- Jun 2017
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of enalapril and folic acid in contrast-induced nephropathy (CIN) (2 arms), sponsored by Zhongda Hospital, Southeast University. Primary endpoints: Incidence of contrast-induced nephropathy and Serum creatinine. Planned start Jun 2017; status: not yet recruiting.
02
Drugs
enalaprilfolic acid
03
Conditions
contrast-induced nephropathy (CIN)
Beyond the preview
Go deeper on ChiCTR-IPR-17011268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17011268.